Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Sarcoma

 

Trabectedin or Dacarbazine Advanced L-Sarcoma (20110545)
A Randomized Controlled Study of YONDELIS (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma Previously Treated With an Anthracycline and Ifosfamide

Investigator: Robin L. Jones, MD;   Conditions: Liposarcoma, Leiomyosarcoma;    Status: Recruiting;   Study ID: NCT01343277

TH-302 + Doxorubicin Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma
A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination with Doxorubicin vs. Doxorubicin Alone in Subjects with Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Investigator: Robin Jones, MD;   Conditions: Sarcoma;    Status: Recruiting;   Study ID: NCT01440088

AZD0530 for Recurrent Osteosarcoma Localized to the Lung (7008)
A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Phase II.5 Study of AZD0530, a Selective Src Kinase Inhibitor, In Patients with Recurrent Osteosarcoma Localized to the Lung

Investigator: Robin L. Jones, MD;   Conditions: Osteosarcoma;    Status: Recruiting;   Study ID: NCT00923286

EURO-E.W.I.N.G. 99 (COG AEWS0331)
European Ewing Tumor Working Initiative of National Groups Ewing Tumour Studies 1999 (EURO-E.W.I.N.G. 99)

Investigator: Doug Hawkins, MD;   Conditions: Sarcoma; Solid Tumors;    Status: Recruiting;   Study ID: NCT00020566

Trabectedin for Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma (20051530)
A Multicenter, Open-label Single-arm Study of YONDELIS® (trabectedin) for Subjects with Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Relapsed or Are Refractory to Standard of Care Treatment

Investigator: Robin L. Jones, MD;   Conditions: Sarcoma;    Status: Recruiting;   Study ID: NCT00210665

Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma (COG ARST0332)
Risk-Based Treatment for Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS)

Investigator: Doug Hawkins, MD;   Conditions: Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma;    Status: Recruiting;   Study ID: NCT00346164

Eribulin or Dacarbazine for Leiomyosarcoma and Liposarcoma (UW11016)
A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma

Investigator: Robin L. Jones, MD;   Conditions: Soft Tissue Sarcoma;    Status: Recruiting;   Study ID: NCT01327885

Pazopanib Hydrochloride Followed By Chemotherapy and Surgery for Soft Tissue Sarcoma
The Effect of Antiangiogenic Therapy With Pazopanib Prior to Preoperative Chemotherapy for Subjects With Extremity Soft Tissue Sarcomas: A Randomized Study to Evaluate Response by Imaging

Investigator: Robin L. Jones, MD;   Conditions: Soft tissue sarcoma;    Status: Recruiting;   Study ID: NCT01446809

Ramucirumab + Docetaxel for Malignant Solid Tumors
A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Docetaxel in Patients With Advanced Malignant Solid Tumors

Investigator: Laura Q.M. Chow, MD;   Conditions: Malignant Solid Tumor;    Status: Closed;   Study ID: NCT01567163

Ramucirumab + Paclitaxel for Malignant Solid Tumors
A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Paclitaxel in Patients With Advanced Malignant Solid Tumors

Investigator: Laura Q.M. Chow, MD;   Conditions: Malignant Solid Tumor;    Status: Closed;   Study ID: NCT01515306

MORAb-004 + Gemcitabine and Docetaxel for Metastatic Soft Tissue Sarcoma
A Study of the Safety and Efficacy of the Combination of Gemcitabine and Docetaxel in Metastatic Soft Tissue Sarcoma

Investigator: Robin L. Jones, MD;   Conditions: Metastatic Soft Tissue Sarcoma;    Status: Recruiting;   Study ID: NCT01574716

Imatinib and BKM120 for 3rd Line GIST Patients
A Multi-arm Dose-finding Phase Ib Multicenter Study of Imatinib in Combination With the Oral Phosphatidyl-inositol 3-kinase (PI3-K) Inhibitor BKM120 in Patients With Gastrointestinal Stromal Tumor (GIST) Who Failed Prior Therapy With Imatinib and Sunitinib

Investigator: Robin L. Jones, MD;   Conditions: 3rd Line GIST;    Status: Recruiting;   Study ID: NCT01468688